Study to Identify the Impact of Denosumab on the Immune System in Patients With HER2 Negative Breast Cancer
Status:
Withdrawn
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
The aim of this prospective, randomized, multicenter, open-label, explorative phase II study
is to identify the impact of (neo)adjuvant denosumab on the systemic immunity and local
immunologic microenvironment in postmenopausal patients with HER2 negative non-metastatic
primary breast cancer.